⌘K
t
e-therapeutics plc announced on 27 April 2022 that it will publish its full year audited results for the year ended 31 January 2022. The Company stated these results are scheduled for release on Wednesday 4 May 2022.
| Date | 27 Apr 2022 |
| Time | 07:00:12 |
| Category | Results |
| ID | 4333J |
e-therapeutics plc
("e-therapeutics" or "the Company")
Notification of Full Year Results Date
Oxford, UK, 27 April 2022 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, will announce its full year audited results for the year ended 31 January 2022 on Wednesday 4 May 2022.
Enquiries:
|
e-therapeutics plc |
|
|
Ali Mortazavi, CEO James Chandler, VP IR & Strategic Communications |
Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk |
|
|
|
|
|
|
|
SP Angel Corporate Finance LLP
|
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Broker
|
|
|
Matthew Johnson/Caroline Rowe (Corporate Finance)
|
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
|
|
|
About e-therapeutics plc
e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.